Brendan D. Curti

Oncology

4805 Northeast Glisan Street
Suite 11N-1
Portland, OR 97213

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 80 publications

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 14, 2026

Five-year survival with tebentafusp in metastatic uveal melanoma.

Five-year survival with tebentafusp in metastatic uveal melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 02, 2026

Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung Cancer.

Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung Cancer.

Journal: JAMA network open

Published: January 28, 2026

Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial.

Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial.

Journal: Nature communications

Published: April 25, 2025

Checkpoint Immunotherapy for Melanoma - Offering Hope for Cure.

Checkpoint Immunotherapy for Melanoma - Offering Hope for Cure.

Journal: The New England journal of medicine

Published: January 03, 2025

Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipients.

Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipients.

Journal: Frontiers in immunology

Published: May 08, 2024

Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.

Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.

Journal: NPJ precision oncology

Published: December 06, 2023

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.

Journal: The New England journal of medicine

Published: October 23, 2023

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 31, 2023

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.

Journal: Cancer

Published: August 14, 2023

Regulation of human and mouse bystander T cell activation responses by PD-1.

Regulation of human and mouse bystander T cell activation responses by PD-1.

Journal: JCI insight

Published: June 21, 2023

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.

Journal: Journal for immunotherapy of cancer

Published: May 26, 2023

Showing 1-12 of 80

Last Updated: 09/26/2026